SBIR-STTR Award

Novel Labeling Method for Multicolor Fluorescence in situ Hybridization (FISH) Probes
Award last edited on: 4/15/2021

Sponsored Program
SBIR
Awarding Agency
NSF
Total Award Amount
$642,016
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Joan Aurichcosta

Company Information

One Cell Systems Inc

100 Inman Street Suite 200
Cambridge, MA 02139
   (617) 868-2399
   yaks@onecell.com
   www.onecell.com
Location: Single
Congr. District: 07
County: Middlesex

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2006
Phase I Amount
$100,000
This Small Business Innovative Research (SBIR) Phase I project aims to develop a novel labeling method for multicolor fluorescence in situ hybridization (FISH) probes that will shorten hybridization time and increase assay sensitivity. The high degree of specificity and accuracy, and the ability to generate rapid results have made FISH the method of choice for identifying chromosomal abnormalities, genetic disease and certain cancers. The proposed labeling method will shorted the hybridization time making FISH analysis more rapid and cost effective without losing the sensitivity required for accurate chromosomal determination

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2007
Phase II Amount
$542,016
This Small Business Innovation Research (SBIR) Phase II research project aims to further develop a panel of multicolor oligonucleotide fluorescence in situ hybridization (FISH) probes for performing preimplantation genetic diagnosis (PGD) and detecting aneuploidies in eggs used for in vitro fertilization (IVF) protocols. The use of oligonucleotides offers advantages such as enhanced specificity and sensitivity, shorter hybridization times as well as a reduction in manufacturing cost when compared to currently available genomic DNA derived probes. The panel that the company plans to develop will cover 8 chromosomes known to be particularly susceptible to deletions and rearrangements and would allow simultaneous detection of any abnormalities that may be associated with them. The development of a panel of probes for the detection of genetic abnormalities in preimplantation embryos will increase the success rate of IVF procedures and thus reduce the financial and emotional cost associated with them. Moreover, use of the proposed labeling method can be useful in a variety of areas outside of PGD, including basic research, clinical diagnostics and cytogenetic testing